Literature DB >> 17460770

Telomere length on chromosome 17q shortens more than global telomere length in the development of breast cancer.

Fariborz Rashid-Kolvear1, Melania Pintilie, Susan J Done.   

Abstract

It is known that total telomere length is shorter in invasive breast cancer than in normal breast tissue but the status of individual telomere lengths has not been studied. Part of the difficulty is that usually telomere length in interphase cells is measured on all chromosomes together. In this study we compared normal breast epithelium, duct carcinoma in situ (DCIS), and invasive duct carcinoma (IDC) from 18 patients. Telomere length was specifically measured on chromosome 17q and was found to be shorter in DCIS and IDC than in normal breast epithelial cells, with more heterogeneity in telomere length in DCIS associated with IDC than in DCIS alone. More importantly, we found that the shortening of telomere on chromosome 17q is greater than the average shortening of all telomeres. This finding indicates that telomere shortening is not simply the result of the end replication problem; otherwise, all telomeres should be subjected to the same rate of telomere shortening. It seems there are mechanisms that preferentially erode some telomeres more than others or preferentially protect some chromosome ends. Our results suggest that the increased level of telomere shortening on 17q may be involved in chromosome instability and the progression of DCIS.

Entities:  

Mesh:

Year:  2007        PMID: 17460770      PMCID: PMC1854852          DOI: 10.1593/neo.07106

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  26 in total

1.  In vivo and in vitro analyses of Myc for differential promoter activities of the human telomerase (hTERT) gene in normal and tumor cells.

Authors:  S Oh; Y H Song; U J Kim; J Yim; T K Kim
Journal:  Biochem Biophys Res Commun       Date:  1999-09-24       Impact factor: 3.575

2.  The hTERT and hTERC telomerase gene promoters are activated by the second exon of the adenoviral protein, E1A, identifying the transcriptional corepressor CtBP as a potential repressor of both genes.

Authors:  Rosalind M Glasspool; Sharon Burns; Stacey F Hoare; Catharina Svensson; W Nicol Keith
Journal:  Neoplasia       Date:  2005-06       Impact factor: 5.715

3.  The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter.

Authors:  Y S Cong; J Wen; S Bacchetti
Journal:  Hum Mol Genet       Date:  1999-01       Impact factor: 6.150

4.  neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group.

Authors:  I L Andrulis; S B Bull; M E Blackstein; D Sutherland; C Mak; S Sidlofsky; K P Pritzker; R W Hartwick; W Hanna; L Lickley; R Wilkinson; A Qizilbash; U Ambus; M Lipa; H Weizel; A Katz; M Baida; S Mariz; G Stoik; P Dacamara; D Strongitharm; W Geddie; D McCready
Journal:  J Clin Oncol       Date:  1998-04       Impact factor: 44.544

5.  Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT).

Authors:  M Wick; D Zubov; G Hagen
Journal:  Gene       Date:  1999-05-17       Impact factor: 3.688

6.  Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA.

Authors:  C Autexier; R Pruzan; W D Funk; C W Greider
Journal:  EMBO J       Date:  1996-11-01       Impact factor: 11.598

7.  Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast.

Authors:  H Fujii; R Szumel; C Marsh; W Zhou; E Gabrielson
Journal:  Cancer Res       Date:  1996-11-15       Impact factor: 12.701

8.  Short telomeres on human chromosome 17p.

Authors:  U M Martens; J M Zijlmans; S S Poon; W Dragowska; J Yui; E A Chavez; R K Ward; P M Lansdorp
Journal:  Nat Genet       Date:  1998-01       Impact factor: 38.330

9.  Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene.

Authors:  I Horikawa; P L Cable; C Afshari; J C Barrett
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

10.  Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells.

Authors:  M Takakura; S Kyo; T Kanaya; H Hirano; J Takeda; M Yutsudo; M Inoue
Journal:  Cancer Res       Date:  1999-02-01       Impact factor: 12.701

View more
  8 in total

1.  Her-2 immunohistochemical expression in oral squamous cell carcinomas is associated with polysomy of chromosome 17, not Her-2 amplification.

Authors:  Dimitrios Papavasileiou; Konstantinos Tosios; Panos Christopoulos; Nikolaos Goutas; Dimitrios Vlachodimitropoulos
Journal:  Head Neck Pathol       Date:  2009-08-22

2.  Telomere length in prospective and retrospective cancer case-control studies.

Authors:  Karen A Pooley; Manjinder S Sandhu; Jonathan Tyrer; Mitul Shah; Kristy E Driver; Robert N Luben; Sheila A Bingham; Bruce A J Ponder; Paul D P Pharoah; Kay-Tee Khaw; Douglas F Easton; Alison M Dunning
Journal:  Cancer Res       Date:  2010-04-15       Impact factor: 12.701

3.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

4.  Individual telomere lengths in chronic myeloid leukemia.

Authors:  Oumar Samassekou; Aimé Ntwari; Josée Hébert; Ju Yan
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

5.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

6.  Telomere attrition in cancer cells and telomere length in tumor stroma cells predict chromosome instability in esophageal squamous cell carcinoma: a genome-wide analysis.

Authors:  Yun-Ling Zheng; Nan Hu; Qing Sun; Chaoyu Wang; Philip R Taylor
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

7.  A prospective investigation of predictive and modifiable risk factors for breast cancer in unaffected BRCA1 and BRCA2 gene carriers.

Authors:  Emer M Guinan; Juliette Hussey; Sarah A McGarrigle; Laura A Healy; Jacintha N O'Sullivan; Kathleen Bennett; Elizabeth M Connolly
Journal:  BMC Cancer       Date:  2013-03-21       Impact factor: 4.430

8.  Chromosome-breakage genomic instability and chromothripsis in breast cancer.

Authors:  Ewa Przybytkowski; Elizabeth Lenkiewicz; Michael T Barrett; Kathleen Klein; Sheida Nabavi; Celia M T Greenwood; Mark Basik
Journal:  BMC Genomics       Date:  2014-07-09       Impact factor: 3.969

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.